Stocks · News reference

OS Therapies Reports Strong Survival Data for Bone Cancer Treatment

Sep 8, 2026, 5:09 PMVandana Singh

OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 7, 2026, 12:40 PMBenzinga Newsdesk
OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary,
OSTX
BenzingaOct 6, 2026, 5:19 PMVandana Singh
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
OS Therapies reports a 72.7% three-year survival rate in its Phase 2b osteosarcoma trial, preparing for global regulatory submissions.
OSTX
BenzingaOct 6, 2026, 1:06 PMBenzinga Newsdesk
OS Therapies shares are trading high after the company announced it achieved a statistically significant final three-year overall survival benefit for OST-HER2-treated patients in its Phase 2b pulmonary metastatic osteosarcoma trial.
OSTX
BenzingaOct 6, 2026, 12:40 PMBenzinga Newsdesk
OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company
OSTX